Table 1.
Table showing expression of various genes and proteins being modulated by fisetin to carry out its anticancer effect.
| Hall Mark | Molecular Target | Transcript Expression | Protein Expression | ||
|---|---|---|---|---|---|
| Upregulation | Downregulation | Upregulation | Downregulation | ||
| Apoptosis | Caspases | CASP9, CASP7, CASP3, CASP6, CASP4, CASP8AP2, CASP2, CASP1 and CASP8 | Caspase-3 and Caspase-8 | ||
| Pro-apoptotic gene | APAF-1, BCL10, BCL2A1, BCL2L1, BCL2L13, BCL2L2, BAD, BAK1 and BAX, BOK, HTRA2, PYCARD, RIPK1, RIPK2, BID, PYCARD, RIPK2 and RIPK1. | Bad, Bax, Bid, Bim, P21, p53, p27, (ligand), cyt-c and HSP27. | |||
| Death receptors | FAS, FASL, CARD6, CARD9, CRADD, DEDD, FADD, TNF, TNFRSFS10A and TNFRSFS10B | Fas, Fas ligand, TNFRII, TNFα, TNF β, TNFRF, TNFSFS, TRAIL R1 to TRAIL R4. | |||
| Anti-apoptotic gene | BCL2, MCL1, BIRC5, and NAIP | Bcl-2, BCL-w, clap-2, HSP70, LIVIN, Survivin and XIAP. | |||
| Sustained cell proliferation | Cell cycle regulation | CCNB1, CCNB2, CCNE2, CDKN2A and CDK4. | |||
| Anti-proliferation and TSGs (Tumour suppressor genes) | PTPRR, FOXO 1, FOXO 3. ATM, ATF2 and TP53 | TERT | |||
| Inflammation and anti-oxidation | IL-2 and MYC, | IL-10 and IL-13 | IL-1α, IL-1β, IL-4, IL-7, IL-11 IL-16, IL-12p70, MIG, MCP-1, MCP-2, MIP-1β, MIP-1γ, MCF, I-309 and EOTAXIN | ||